Century Therapeutics, Inc. IPSC

Rank #2236 · Nasdaq · $0.3B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

28.0

P/E

-2.1

P/B

1.44

ROE

-68.5%

Op. Margin

-2096.5%

Debt Ratio

104%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -2.1x, P/B 1.44x. Ranks in the top 59% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -68.5%. Ranks in the top 94% of the universe.

Safety ★★★☆☆

Average

Debt ratio 104%. Ranks in the top 41% of the universe.

Growth ★★★★★

Excellent

Revenue growth of 194.8% year over year. Ranks in the top 2% of the universe.

Growth is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2021	–	$-0.1B	$-0.1B	$-0.1B	–	-36
2022	$0.0B	$-0.1B	$-0.1B	$-0.1B	-1825.0	-39
2023	$0.0B	$-0.1B	$-0.1B	$0.4B	-2574.2	46
2024	$0.0B	$-0.1B	$-0.1B	$0.3B	-6556.9	58
2025	$0.0B	$-0.1B	$-0.1B	$0.2B	-2096.5	104